Objective There are no rules to predict the time to infectivity negative conversion based on sputum smear conversion or culture conversion during chemotherapy in smear-positive tuberculosis patients. We aimed to develop and validate rules of sputum smear grades and cavitations in the lungs due to tuberculosis. Methods This study was a retrospective cohort study that consisted of development (n=158, 64±19 years of age) and validation (n=214, 63±20 years of age) steps in different cohorts. We developed a rule with pretreatment smear grades and the existence of cavitations in the lungs due to tuberculosis as independent variables and the duration to infectivity negative conversion as the dependent variable in a Cox hazard model. The smear grade indicating the pretreatment bacterial load was classified into four grades according to the Japanese guidelines. The presence of cavitations was assessed on X-ray. Infectivity conversion was defined according to the criteria of the Japanese Ministry of Health, Labour and Welfare: a patient is currently receiving proper treatment and shows clinical improvement and sputum smears and cultures in any combination are consecutively negative three times. Results <DEVELOPMENT> We developed an "Infectivity Conversion Score" classifying each patient with a smear grade of I though IV and assessing the existence of cavitations in the lungs due to tuberculosis. <VALIDATION> The median time to infectivity conversion in the validation cohort was 13, 22, 35 and 50 days for Infectivity Conversion Scores I through IV, respectively (p<0.001). Conclusion We developed and validated Infectivity Conversion Scores.
Introduction
The ultimate goals of treatment of tuberculosis are to cure the individual and to minimize the transmission of Mycobacterium tuberculosis to other persons in the community (1) . Inadequate infection control in the health care system may result in outbreaks of tuberculosis, as have occurred in the last century. For proper infection control, evaluating infectivity negative conversion is a principal issue when treating tuberculosis patients (2) .
Among a variety of parameters used to evaluate tuberculosis patients, previous studies have revealed that profound pretreatment bacterial load determination based on sputum smear examinations and the existence of cavitations in the lungs due to tuberculosis, which are immediately accessible at the beginning of treatment, are considerable risk factors for delayed smear and culture conversion (3) (4) (5) (6) (7) . These studies demonstrate the impact of pretreatment status on smear and culture conversion. However, no studies have evaluated the direct relationship between pretreatment status and infectivity negative conversion, as judged on smear or culture conversion. We believe that confirming culture conversion along with smear conversion is vital for determining infectivity conversion because relying on persistent positive smear results without assessing sputum cultures cannot differentiate between viable and dead tuberculosis bacilli (4) .
Tuberculosis infection status would preferably be evaluated with frequent sputum and culture conversion during antibiotic treatment. However, predicting infectivity negative conversion is often difficult because of the low repeatability of sputum smears and cultures, persistent positive smear results for dead bacilli, resource limited situations preventing frequent culture and/or smear testing and long incubation times for sputum cultures (8) . Therefore, if a simple rule could predict the time to infectivity conversion, it would provide useful information for clinicians. In this study, we developed and validated a rule to predict time to infective conversion judged on sputum smear conversion or culture conversion during chemotherapy in tuberculosis patients.
Materials and Methods
We first developed a scoring system using a data set of patients belonging to Yokohama City University Hospital. Thereafter, we validated the scoring system using another data set of patients belonging to Fukujuji Hospital. Wasson recommended this two-step method because the validation step can estimate the accuracy of the scoring system (9). Many previously established scoring systems have been developed and validated using this two-step method. In the development step, our goal was to develop an Infectivity Conversion Score. We first determined how many smear grade increases were equivalent to the existence of cavitations using a Cox regression hazard model. The model comprised a smear grade and the existence of cavitations on X-ray as the independent variables and time to infective conversion as the dependent variable. Next, we determined the Tentative Infectivity Conversion Score by adding the smear grade (0-3) to the cavitation score. If the adjacent Tentative Infectivity Conversion Score, which was expressed as an integer, had an approximate (<7 days) median time to infective conversion, it was merged into the same Infectivity Conversion Score category. Time to infective conversion among each score was re-evaluated in the validation cohort.
Patients
Patients were recruited from two hospitals located in different regions: Yokohama City University Hospital, Yokohama, Japan, a university hospital with 638 beds, including 16 isolation beds for tuberculosis, and Fukujuji Hospital, Tokyo, Japan, a community-based teaching hospital with 339 beds, including 60 isolation beds for tuberculosis. All consecutive patients admitted to the isolation ward with a primary diagnosis of lung tuberculosis satisfying the following criteria were included. The inclusion criteria were as follows: (i) active infectious lung tuberculosis diagnosed based on sputum smear and culture; (ii) newly diagnosed disease (patients who had already started treatment in another clinic or hospital were excluded); and (iii) age ! 20 years. The exclusion criteria were as follows: (i) multidrug-resistant tuberculosis (MDR-TB) infection, defined as resistance to both rifampicin and isoniazid; (ii) human immunodeficiency virus (HIV) infection; (iii) death before infectivity conversion; and (iv) transfer out of the hospital (if a patient refused treatment or was transferred to another hospital before discontinuing isolation). Patients at Yokohama City University were evaluated between January 2008 and September 2011, whereas patients at Fukujuji Hospital were evaluated between January 2009 and December 2009, based on the admission date. All included patients exhibited infectivity conversion by the time of data acquisition. No patient was lost during follow-up. This study was approved by the Yokohama City Hospital Institutional Review Board and the Fukujuri Hospital Institutional Review Board. The need for informed consent was waived for this study due to patient anonymity and the observational nature of the study.
Measurements
HIV status and susceptibility to anti-tuberculosis drugs were assessed in all patients. Sputum tests for both smear and culture were conducted on consecutive days on admission and four times a month during each patient's hospital course. The sputum smears were prepared according to the concentrated preparation method, screened using the auramine-O fluorochrome procedure and then reconfirmed with Ziehl-Neelsen staining (8) . The smear grade indicating the pretreatment bacterial load was classified into four grades according to the Japanese guidelines using the ZiehlNeelsen stain (×1,000): (±), ! 1 acid-fast bacilli (AFB)/ 300 fields; (+), ! 1 AFB/ 100 fields; (2+), ! 1 AFB/ 10 fields; and (3+), ! 10 AFB/ fields (8, 10) . The sputum smears were checked two to five times on admission, and the highest smear grade was adopted. Cultivation of Mycobacterium was performed on egg-based medium (Lowenstein-Jensen) or liquid-based medium (Middleback7H9). The culture periods were four and six weeks for the egg-based and liquid-based mediums, respectively. The existence of cavitations in the lungs due to tuberculosis was assessed on X-ray, not on computed tomography, at the time of admission. The presence of cavitations on X-ray was confirmed by the agreement of at least four pulmonologists in charge of each patient, not by the investigators. Verifying the presence of cavitations on X-ray in all tuberculosis patients in Japan has been a strict requirement for decades and is always documented.
Treatment
A daily combined four-drug standard regimen of isoniazid, rifampicin, pyrazinamide and ethambutol for two months followed by combination therapy with isoniazid and rifampicin is the preferred regimen (1). In this study, a three-drug standard regimen without pyrazinamide was often chosen for the elderly and patients with chronic liver disease at risk for drug-induced liver injury. Other regimens were permitted when drug-resistant tuberculosis bacilli or comorbidity prevented administration of the standard regimen. All patients were admitted to the isolation ward and antibiotic treatment was initiated immediately after smear-positive lung tuberculosis was confirmed. The patients were directly observed (1, 11) by well-trained medical staff. If a patient had an ingestion or absorption problem, administration via a nasogastric tube or use of an alternative intravenous drug were considered.
Outcomes
Infectivity (negative) conversion was comprehensively judged according to the definition of the Japanese Ministry of Health, Labour and Welfare: a patient is currently receiving proper treatment and shows clinical improvement and sputum smears and cultures in any combination are consecutively negative three times (12) . The date of infectivity conversion was retrospectively defined as the date when the first consecutive sputum sample satisfying the criteria was collected (5) . Time to infectivity conversion was defined as the duration from the date of admission to the date of infectivity conversion.
Statistical analyses
Spearman's rank correlation, Cox proportional hazard analyses, Kaplan-Meier curves, the log-rank test, the Kruskal-Wallis test and the Wilcoxon rank-sum test were used as appropriate. The rejection region was p=0.05. For Spearman's rank correlation, |r| <0.2 was not regarded as meaningful, even if p was significant. Sign "±" expressed the SD, not the SE. Smear grades (±), (1+), (2+) and (3+) were regarded as 0, 1, 2 and 3, respectively, for the Cox proportional hazard analyses. The data analysis was performed with Excel Toukei (SSRI, Tokyo, Japan) and GraphPad Prism ver. 5 (GraphPad Software Inc., USA).
Results

Development
The development cohort consisted of 106 men (67.1%) and 52 women (32.9%), whose mean age was 64±19 years. Sixty-four patients (40.5%) had cavitations on X-ray, 35 patients (22.2%) had smear grade (±), 41 patients (25.9%) had smear grade (1+), 32 patients (20.3%) had smear grade (2+) and 50 patients (31.6%) had smear grade (3+) ( Table 1) . The time to infectivity negative conversion among the entire development cohort was as follows: median: 28 days, average: 33±22 days and range: 6-117 days.
Using the Cox proportional hazard model, the coefficients to predict infectivity conversion were -0.45 for smear grade and -0.52 for cavitations. Hence, the existence of cavitations was equivalent to one (=1.2=-0.52/-0.45) increase in the smear grade. Therefore, the tentative Infectivity Conversion Scores were defined as follows: smear grade (0 through 3) + cavitation (0 or 1). For example, if a patient had a smear grade of 2 (2 points) and cavitations (1 point), then the Tentative Infectivity Conversion Score was 3 (=2+1) points. Time to infective conversion in the development cohort was prolonged as the Tentative Infectivity Conversion Score increased ( Table 2 ). As patients with Tentative Infectivity Conversion Scores of 0 and 1 had approximate median times to infectivity conversion (17-15<7), tentative scores of 0 and 1 were merged into the same category (Tables 2, 3 ): a patient with a Tentative Infectivity Conversion Score of 0 or 1 had an Infectivity Conversion Score of I and a patient with a Tentative Infectivity Conversion Score of 2, 3 or 4 had an Infectivity Conversion Score of II, III or IV, respectively. The time to infective conversion in the development cohort increased as the Infectivity Conversion Score increased (Spearman's correlation: r=0.57, p<0.001).
We also evaluated whether the treatment regimen or baseline patient characteristics other than smear grade and the presence of cavitations affected the time to infectivity conversion in the development cohort. Patient age (r=-0.17, p= 0.038), hemoglobin (r=0.09, p=0.280),total protein (r=0.16, p=0.0504), AST (r=0.10, p=0.193) and creatinine (r=-0.04, p=0.644) did not show meaningful Spearman's rank correla- and resistance to one or more key drugs (p=0.318) were not found to be associated with time to infectivity conversion when analyzed with the Wilcoxon rank-sum test. A comparison of three treatment groups, including the four-drug standard regimen with pyrazinamide, the three-drug standard regimen without pyrazinamide and the non-standard regimen, did not show any differences in time to infectivity conversion (Kruskal-Wallis: p=0.348).
Validation
The validation cohort consisted of 149 men (69.6%) and 65 woman (30.4%), whose mean age was 63±20 years. Ninety-six patients (44.9%) had cavitations on X-ray, 17 patients (12.6%) had smear grade (±), 37 patients (17.3%) had smear grade (1+), 53 patients (24.8%) had smear grade (2+) and 97 patients (45.3%) had smear grade (3+) ( Table 1) . The time to infectivity conversion among the entire validation cohort was as follows: median: 29 days, average: 33±23 days and range: 4-125 days.
The median time to infective conversion was 13, 22, 35 and 50 days among patients with Infectivity Conversion Scores of I, II, III and IV, respectively ( Table 4 ). The time to infective conversion increased as the Infectivity Conversion Scores increased (Spearman's correlation: r=0.59, p< 0.001). The accumulative incidence of infective conversion was significantly different among the patients with each Conversion Score (Figure) .
Discussion
We developed and validated a scoring system to estimate the time to infectivity negative conversion. This is the first predicting rule for infectivity conversion judged based on sputum smear or culture conversion. Smear grade (3+) indicates a 3,000-fold increase in the number of bacilli in sputum compared with the smear grade (±). Cavitations formed from liquefied caseous necrotic material contain 10^5 as many bacilli as caseous foci (13) . Considering that it takes two weeks to achieve a 1,000-fold reduction in the count of colony-forming units (14) , it is acceptable that smear grades and cavitations correlate with the time to infectivity conversion. Wang reported that the median duration to smear conversion is 11 days among patients with the lowest smear grade, 24 days among patients with the highest smear grade, 14 days among patients without cavitations and 39 days among patients with cavitations (4). These findings are compatible with the values reported in our study. Even when patients have a high smear grade and cavitations, those receiving appropriate susceptible chemotherapy under direct observation will almost always be culture negative by the end of the fourth month. Therefore, four months is usually regarded as the cutoff for treatment failure (1). All patients but one in our cohorts showed infective conversion by the 120th day. The one patient in the validation cohort showed infective conversion on the 125th day. We also evaluated the associations between other factors and the time to infectivity conversion. However, none of these factors were as strong in predicting infectivity conversion as the smear grade and the existence of cavitations.
It is important to acknowledge the limitations of simple criteria for evaluating infectivity negative conversion because transmission of tuberculosis depends on various conditions (15) . However, practically acceptable criteria are needed to estimate infectivity conversion. The Centers for Disease Control and Prevention proposed criteria for discontinuing isolation in 1994: all tuberculosis patients should remain in isolation while hospitalized until they have had three consecutive negative sputum smears collected on different days and they demonstrate clinical improvement (2) . Although it is one of the most widely used criterion for determining infectivity negative conversion, relying on persistent positive smear results without assessing sputum cultures cannot differentiate between viable and dead tuberculosis bacilli (4). In 2002, Ramarokoto reported that, among 152 Furthermore, post-treatment smear-positive culture-negative results are more frequently observed in patients treated with a rifampicin-containing regimen (17) . These studies obviously indicate that obtaining persistent positive smear results after the administration of the current standard regimen, which usually contains rifampicin, is not always relevant to active bacilli. The Japanese Society for Tuberculosis proposed another set of criteria judging infectivity conversion in individual patients using both sputum smear conversion and culture conversion (18) . The Japanese Ministry of Health, Labour and Welfare published guidelines (12) for discharge criteria for isolated tuberculosis patients based on the criteria proposed by The Japanese Society for Tuberculosis. We believe that the Japanese criteria are therefore more accurate for determining infectious conversion, as long as repeated sputum cultures can be obtained. The rough time estimation to infectivity conversion proposed in this study would help physicians to make treatment decisions, especially when repeated smears and cultures are not available during treatment due to resource limitations and when some still-infectious patients need to be discharged due to limited numbers of available isolation beds (7) . For example, a patient with an Infectivity Conversion Score of II would probably (95%) be noninfective after 53 days of appropriate treatment (Table 4) .
Our study has several limitations. First, our cohorts did not include patients with MDR-TB, patients without susceptibility tests or patients with possible nonadherence. This scoring system should not be used in such patients. Second, this study was designed as a retrospective cohort study. Nonetheless, we believe that this study's strengths reside in the clear presentation of the inclusion and exclusion criteria. Third, our cohorts did not include HIV patients. Because previous studies have demonstrated that HIV status does not prolong the time to infective conversion (5), we believe that our scoring would be helpful for estimating infectivity conversion among HIV patients, although this requires further investigation. Fourth, sputum exams are not always reproducible (not producing the same results repeatedly), which is a common weak point observed with some criteria such as the Japanese criteria mentioned above (18, 12) and the isolation discontinuing criteria proposed by the Centers for Disease Control and Prevention (three consecutive negative sputum AFB smears collected on different days) (2) . Even though they are not satisfactorily reproducible, sputum exams are regarded to be the most reliable method to judge infectivity in individual patients in the daily clinical setting. To overcome this problem, sputum exams are usually repeated three times. Fifth, we did not evaluate cavitations comprehensively. Evaluating the size and number of cavitations may improve the accuracy of the scoring system. On the other hand, these strategies diminish the simplicity of the scoring system. Evaluating cavitations using CT scans is very powerful and attractive; however, CT imaging is not readily available in some tuberculosis-prevalent developing countries. Our goal here is to establish a simple scoring system accessible even in developing countries.
In conclusion, we developed and validated a rule to predict the time to infective conversion in tuberculosis inpatients without HIV and/or MDR-TB treated under directly observed therapy. The rule determined by the smear grade and the presence of cavitations on X-ray can predict the time to infective conversion judged on sputum smear or culture conversion.
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